
Gelomics revolutionises drug development by providing a more predictive, ethical alternative to traditional cell and animal models. We enable scientists to grow functional human microtissues using our AI-powered technology, which significantly improves the accuracy of drug response predictions. This innovation reduces costs, shortens development timelines, and decreases reliance on animal testing, offering a more efficient and humane approach to pharmaceutical research. Our mission is to accelerate therapeutic breakthroughs, ensuring faster, safer, and more humane medical advancements.
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.